Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2181308 with idarubicin and cytarabine in relapsed or refractory AML
NCT00620321Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Jan 2010
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gataparsen in acute myeloid leukemia (AML) and Chronic Myeloid Leukemia (CML), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 6.7 months. Started Mar 2008; status: completed.
02
Drugs
gataparsen
03
Conditions
acute myeloid leukemia (AML)Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00620321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00620321.